Heart Failure With Preserved Ejection Fraction (Diastolic Dysfunction)
Authors: Theo Meyer, Jeffrey Shih, Gerard Aurigemma
Journal: Annals of Internal Medicine (2013)

In the Clinic1 January 2013Heart Failure With Preserved Ejection Fraction (Diastolic Dysfunction)Theo Meyer, MD, DPhil, Jeffrey Shih, MD, Gerard Aurigemma, MD, Deborah Cotton, MD, MPH, Darren Taichman, MD, PhD, and Sankey Williams, MDTheo Meyer, MD, DPhil, Jeffrey Shih, MD, Gerard Aurigemma, MD, Deborah Cotton, MD, MPH, Darren Taichman, MD, PhD, and Sankey Williams, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-158-1-201301010-01001 SectionsSupplemental MaterialAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Heart failure (HF) is a serious health problem, with an estimated incidence of 660 000 cases per year in the United States, and a prevalence of more than 5 million. HF is the most common discharge diagnosis among patients older than 65 years and the primary cause of re-admission within 60 days. As the population ages, HF is expected to become an even greater public health problem.In contrast to HF patients with a reduced ejection fraction (HFrEF), up to 50% of patients with signs and symptoms of HF have normal or preserved left ventricular ejection fraction (HFpEF), also called ...References1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-9. [PMID: 16855265] Google Scholar2. Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail. 2011;13:18-28. [PMID: 20685685] Google Scholar3. Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction. Eur Heart J. 2007;28:2539-50. [PMID: 17428822] Google Scholar4. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. Circulation. 2009;119: 1977-2016. [PMID: 19324967] Google Scholar5. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure—abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004;350:1953-9. [PMID: 15128895] Google Scholar6. Stein PK, Tereshchenko L, Domitrovich PP, Kleiger RE, Perez A, Deedwania P. Diastolic dysfunction and autonomic abnormalities in patients with systolic heart failure. Eur J Heart Fail. 2007;9:364-9. [PMID: 17123863] Google Scholar7. Borlaug BA, Redfield MM. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation. 2011;123:2006-13; discussion 2014. [PMID: 21555723] Google Scholar8. Zile MR. Heart failure with preserved ejection fraction: is this diastolic heart failure? [Editorial]. J Am Coll Cardiol. 2003;41:1519-22. [PMID: 12742292] Google Scholar9. Udelson JE. Heart failure with preserved ejection fraction. Circulation. 2011;124 :e540-3. [PMID: 22105201] Google Scholar10. Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation. 2009;119: 3070-7. [PMID: 19506115] Google Scholar11. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355:260-9. [PMID: 16855266] Google Scholar12. Liao L, Jollis JG, Anstrom KJ, et al. Costs for heart failure with normal vs reduced ejection fraction. Arch Intern Med. 2006;166:112-8. [PMID: 16401819] Google Scholar13. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305-13. [PMID: 12151467] Google Scholar14. Velagaleti RS, Massaro J, Vasan RS, Robins SJ, Kannel WB, Levy D. Relations of lipid concentrations to heart failure incidence: the Framingham Heart Study. Circulation. 2009;120:2345-51. [PMID: 19933936] Google Scholar15. Doehner W, Rauchhaus M, Ponikowski P, et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol. 2005;46: 1019-26. [PMID: 16168285] Google Scholar16. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001; 161:996-1002. [PMID: 11295963] Google Scholar17. MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, et al; CHARM Investigators. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure. Eur Heart J. 2008;29:1377-85. [PMID: 18413309] Google Scholar18. Kannel WB. The Framingham Study: historical insight on the impact of cardiovascular risk factors in men versus women. J Gend Specif Med. 2002;5:27-37. [PMID: 11974672] Google Scholar19. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241:2035-8. [PMID: 430798] Google Scholar20. Aurigemma GP, Gaasch WH. Clinical practice. Diastolic heart failure. N Engl J Med. 2004;351: 1097-105. [PMID: 15356307] Google Scholar21. Scantlebury DC, Borlaug BA. Why are women more likely than men to develop heart failure with preserved ejection fraction? Curr Opin Cardiol. 2011;26:562-8. [PMID: 21993357] Google Scholar22. Zile MR, Gottdiener JS, Hetzel SJ, et al; I-PRESERVE Investigators. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation. 2011;124:2491-501. [PMID: 22064591] Google Scholar23. Chobanian AV, Bakris GL, Black HR, et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-52. [PMID: 14656957] Google Scholar24. Piller LB, Baraniuk S, Simpson LM, et al; ALLHAT Collaborative Research Group. Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation. 2011;124:1811- 8. [PMID: 21969009] Google Scholar25. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association. Medical management of hyperglycaemia in type 2 diabetes mellitus. Diabetologia. 2009;52:17-30. [PMID: 18941734] Google Scholar26. Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;356: 1955-64. [PMID: 11130523] Google Scholar27. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-53. [PMID: 10639539] Google Scholar28. Beckett NS, Peters R, Fletcher AE, et al; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-98. [PMID: 18378519] Google Scholar29. Davis BR, Kostis JB, Simpson LM, et al; ALLHAT Collaborative Research Group. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation. 2008;118:2259-67. [PMID: 19001024] Google Scholar30. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-62. [PMID: 8413456] Google Scholar31. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med. 1993;118:129-38. [PMID: 8416309] Google Scholar32. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355:253-9. [PMID: 10675071] Google Scholar33. Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation. 2005;112:357-63. [PMID: 16009792] Google Scholar34. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002;105:1387-93. [PMID: 11901053] Google Scholar35. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194-202. [PMID: 12517230] Google Scholar36. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009;22:107-33. [PMID: 19187853] Google Scholar37. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32:670-9. [PMID: 21138935] Google Scholar38. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010;3:588-95. [PMID: 20543134] Google Scholar39. Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation. 2000;101:2118-21. [PMID: 10790356] Google Scholar40. Yturralde RF, Gaasch WH. Diagnostic criteria for diastolic heart failure. Prog Cardiovasc Dis. 2005;47: 314- 9. [PMID: 16003646] Google Scholar41. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95:948-54. [PMID: 15820160] Google Scholar42. Grewal J, McKelvie RS, Persson H, et al. Usefulness of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. Am J Cardiol. 2008;102:733-7. [PMID: 18773998] Google Scholar43. Wann LS, Curtis AB, January CT, et al; 2011 Writing Group Members. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation. Circulation. 2011;123:104-23. [PMID: 21173346] Google Scholar44. Yusuf S, Pfeffer MA, Swedberg K, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777-81. [PMID: 13678871] Google Scholar45. Meta-analysis Global Group in Chronic Heart Failure. The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J. 2012;33:1750-7. [PMID: 21821849] Google Scholar46. Zile MR, Gaasch WH, Anand IS, et al; I-Preserve Investigators. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circ. 2010;121:1393-405. [PMID: 20231531] Google Scholar47. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. Circulation. 2009;119:e391-479. [PMID: 19324966] Google Scholar48. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA. 2002;288:2981-97. [PMID: 12479763] Google Scholar49. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41-6. [PMID: 12867233] Google Scholar50. Solomon SD, Janardhanan R, Verma A, et al; Valsartan In Diastolic Dysfunction (VALIDD) Investigators. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet. 2007;369:2079-87. [PMID: 17586303] Google Scholar51. Wyse DG, Waldo AL, DiMarco JP, et al; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-33. [PMID: 12466506] Google Scholar52. Van Gelder IC, Hagens VE, Bosker HA, et al; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-40. [PMID: 12466507] Google Scholar53. Olsson LG, Swedberg K, Ducharme A, et al; CHARM Investigators. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction. J Am Coll Cardiol. 2006;47:1997-2004. [PMID: 16697316] Google Scholar54. Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006;114:397-403. [PMID: 16864724] Google Scholar65. Hsu LF, Jaïs P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med. 2004;351:2373-83. [PMID: 15575053] Google Scholar56. Desai AS, Lewis EF, Li R, et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Am Heart J. 2011;162: 966-972.e10. [PMID: 22137068] Google Scholar57. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124:164-74. [PMID: 21709061]. Google Scholar58. Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study). Accessed at http://clinicaltrials.gov/ct2/show/NCT00763867 on September 4, 2012. Google Scholar59. USDA/USDHHS. Dietary Guidelines for Americans 2010. Washinngton, DC: US Gov Print Office; 2010. Google Scholar60. Kitzman DW, Brubaker PH, Morgan TM, Stewart KP, Little WC. Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Circ Heart Fail. 2010;3:659-67. [PMID: 20852060] Google Scholar61. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998;98:2282-9. [PMID: 9826315] Google Scholar62. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33:1948-55. [PMID: 10362198] Google Scholar63. Cohn JN, Johnson G. Heart failure with normal ejection fraction. The V-HeFT Study. Veterans Administration Cooperative Study Group. Circulation. 1990;81:III48-53. [PMID: 2404638] Google Scholar64. Gottdiener JS, McClelland RL, et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. Ann Intern Med. 2002;137:631-9. [PMID: 12379062] Google Scholar65. O'Connor CM, Gattis WA, Shaw L, Cuffe MS, Califf RM. Clinical characteristics and long-term outcomes of patients with heart failure and preserved systolic function. Am J Cardiol. 2000;86:863-7. [PMID: 11024402] Google Scholar66. Persson H, Lonn E, Edner M, et al; Investigators of the CHARM Echocardiographic Substudy-CHARMES. Diastolic dysfunction in heart failure with preserved systolic function. J Am Coll Cardiol. 2007;49:687-94. [PMID: 17291934] Google Scholar67. Ahmed A, Aronow WS, Fleg JL. Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function. Am Heart J. 2006;151:444-50. [PMID: 16442912] Google Scholar68. Hillege HL, Nitsch D, Pfeffer MA, et al; Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113:671-8. [PMID: 16461840] Google Scholar69. Pacing for Heart Failure With Preserved Ejection Fraction. Accessed at (HFpEF) http://clinicaltrials.gov/ct2/show/NCT01045291 on 4 September 2012. Google Scholar Author, Article, and Disclosure InformationAuthors: Theo Meyer, MD, DPhil; Jeffrey Shih, MD; Gerard Aurigemma, MD; Deborah Cotton, MD, MPH; Darren Taichman, MD, PhD; Sankey Williams, MD PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byChallenges in the management of people with heart failure with preserved ejection fraction (HFpEF) in primary care: A qualitative study of general practitioner perspectivesEvaluation of Ibrutinib Cardiotoxicity By Comparative Use of Speckle-Tracking Technique and BiomarkersRetrospective evaluation of echocardiographic variables for prediction of heart failure hospitalization in heart failure with preserved versus reduced ejection fraction: A single center experienceClinical significance of diastolic late mitral annular velocity in heart failure with preserved ejection fractionThe Heart Failure with Preserved Ejection Fraction Conundrum—Redefining the Problem and Finding Common Ground?Breast Cancer PreventionMethod for the unique identification of hyperelastic material properties using full-field measures. Application to the passive myocardium material responsePulmonary vascular volume, impaired left ventricular filling and dyspnea: The MESA Lung StudyHeart Failure with Normal Left Ventricular Ejection Fraction (HFNEF)Intimate partner violence and women's cancer quality of lifeHyperdynamic left ventricle on radionuclide myocardial perfusion imaging (RNMPI): A marker of diastolic dysfunction in patients presenting with dyspnea on exertionAge- and gender-specific changes of tricuspid annular motion velocities in normal heartsComparative Mortality among People Diagnosed with HIV Infection or AIDS in the U.S., 2001–2010Pharmacotherapy of Heart Failure with Preserved Ejection FractionPulmonary hypertension in heart failure with preserved ejection fractionAssociation of serum total bilirubin levels with diastolic dysfunction in heart failure with preserved ejection fractionLeft Atrial Phasic Function and Mechanics in Women with Subclinical Hypothyroidism: The Effects of Levothyroxine TherapyAddressing Glaucoma in the Developing Countries of the Asia Pacific RegionPrecipitating Factors in Younger and Older Adults with Decompensated Chronic Heart Failure: Are They Different?Through Thick and Thin 1 January 2013Volume 158, Issue 1 Page: ITC1-1 Keywords Atrial fibrillation Blood pressure Cardiovascular therapy Diuretics Exercise Heart Heart failure Heart rate Hypertension Stable coronary artery disease ePublished: 1 January 2013 Issue Published: 1 January 2013 Copyright & PermissionsCopyright © 2013 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...